GlycoMimetics (NASDAQ:GLYC – Get Free Report)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. Several other equities analysts also recently issued reports on GLYC. StockNews.com downgraded shares of GlycoMimetics from a “hold” rating to a “sell” rating in […]
GlycoMimetics (NASDAQ:GLYC – Get Free Report)‘s stock had its “neutral” rating reiterated by investment analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. Several other research analysts also recently issued reports on the stock. StockNews.com downgraded shares of GlycoMimetics from a “hold” rating to a “sell” rating in a research report […]
Intellectus Partners LLC decreased its holdings in GlycoMimetics, Inc. (NASDAQ:GLYC – Free Report) by 18.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 50,720 shares of the biotechnology company’s stock after selling 11,255 shares during the quarter. Intellectus Partners LLC owned 0.08% […]
StockNews.com upgraded shares of GlycoMimetics (NASDAQ:GLYC – Free Report) from a sell rating to a hold rating in a research note published on Tuesday. Separately, Capital One Financial began coverage on GlycoMimetics in a report on Friday, December 22nd. They issued an overweight rating and a $12.00 price objective for the company. Get Our Latest […]
GlycoMimetics (NASDAQ:GLYC – Get Free Report) and NLS Pharmaceutics (NASDAQ:NLSP – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Earnings & Valuation This table compares GlycoMimetics and NLS […]